Skip to Content

Zyprexa (olanzapine) - Mar 22, 2004

Audience: Neuropsychiatric healthcare professionals

FDA and Lilly notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Zyprexa. FDA has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add this Warning statement to labeling.

[March 2004 Letter - Lilly] PDF version
[January 2004 Revised Label - Lilly]

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.